
Feature|Articles|August 28, 2026
Preventing Batch Loss: The Growing Role of Preventive and Predictive Maintenance
Author(s)Israel Ortiz
With biopharma batch failures averaging every 40 weeks, predictive maintenance and connected monitoring are becoming critical quality levers.
Advertisement
Advertisement
Pharmaceutical manufacturers operate under some of the strictest quality requirements in any industry. Even small deviations in a facility’s environmental conditions can compromise product stability and risk batch losses that can cost manufacturers millions of dollars in lost product, investigations, and production delays. Despite improvements in manufacturing technology, batch failures still occur due to contamination, operator error, and equipment failure. On average, biopharmaceutical manufacturers experience a failure every 40 weeks.
Related to this article

FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.

FDA Commissioner’s National Priority Voucher program reportedly in limbo for expedited drug reviews.

FDA has approved Merck KGaA’s Pimjetmi, an oral CSF-1R inhibitor, for adults with symptomatic tenosynovial giant cell tumors.

FDA approves Bayer’s asundexian as the first Factor XIa inhibitor for secondary stroke prevention, the FDA requires a new safety label warning across all GLP-1 receptor agonists for a potential NAION risk, and AstraZeneca acquires Omniose to add a bioconjugation platform to its vaccine pipeline.

FDA approves Bayer’s asundexian (Sunharbo), the first Factor XIa inhibitor, for secondary stroke prevention.

Hims & Hers partners with Eli Lilly to sell Zepbound and Foundayo directly on its platform, Novo Nordisk terminates its research collaboration with Korro Bio, and the FDA grants accelerated approval to Johnson & Johnson’s Rybrevant Faspro in head and neck cancer.

ANI Pharmaceuticals makes an offer to acquire Egetis Therapeutics, as Egetis separately agrees to sell its priority review voucher for $190 million.
Advertisement
Advertisement

